TABLE 4 Recovery of KAE609 and its metabolites in human excreta (expressed as percentage of dose) after an oral dose of 300 mg [14C] KAE609
The pooled urine and fecal samples were extracted and analyzed by LC-MS/MS for metabolic profiling. The HPLC separation of KAE609 and metabolites was performed using a Zorbax SB-C18 column, as described in the Materials and Methods.